Project Grant RM1NS140316
Award Date 9/5/25
Completion Date 8/31/30
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,320,580 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in Missouri. The grant will fund preclinical studies to evaluate the analgesic potential of a novel, peripherally-restricted cannabinoid type 1 receptor (CB1R) agonist called VIP36. The key objectives are to assess VIP36's efficacy in mouse models of post-traumatic headache,...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This Project Grant award of $153,000.00, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a 6-month longitudinal study examining the relationships between naturalistic cannabis use, pain perception, and functioning (e.g., pain-related disability, physical activity, sleep) in the daily lives of young adults with chronic pain. The study will use an ecological momentary assessment burst design to capture...
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $137,619.00 to the University of Washington to investigate the role of tetrahydrocannabinol (THC) in mediating pain signaling in the basolateral amygdala (BLA). The central hypothesis is that THC acts as a partial agonist at the cannabinoid 1 receptor (CB1R) to decrease excitatory BLA neuronal activity and pain behaviors during chronic pain. The research aims to...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a $1,955,201 Cooperative Agreement to Cincinnati Children's Hospital Medical Center under the NIH Drug Use and Addiction Research Programs (CFDA 93.279). The 5-year award, effective September 19, 2025 through July 31, 2030, will support research to better understand the biopsychosocial determinants of pediatric-onset chronic musculoskeletal pain. The research will...
- This federal Project Grant award in the amount of $5,057,591 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct a comprehensive, prospective observational study with 2,400 emergency department patients seeking care for acute pain. The study aims to: 1) characterize clinically-informed pain phenotypes, 2)...
- This Project Grant award for $668,131 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct research on chronic neuropathic pain (CNP) and understand how alterations in dopamine function and reward processing may contribute to the affective symptoms of CNP. The research aims to quantify changes in dopamine release in the nucleus...
- The University of Miami is conducting a research project under a $1,109,446 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). The project, funded through the Drug Abuse and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-opioid analgesic based on gene therapy targeting the carbonic anhydrase-8 (CA8) protein to treat chronic pain associated with knee osteoarthritis. The...
- This federal Project Grant award of $385,638 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to conduct research on the neurobehavioral consequences of chronic exposure to synthetic cannabinoids, also known as "synthetic marijuana", across different stages of lifespan development and between sexes. The research aims to elucidate the...
- This Project Grant award of $4,649,740 from the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health) under the Drug Use and Addiction Research Programs (CFDA 93.279) is funding research to develop network-based models for understanding inter-individual differences in the progression of chronic musculoskeletal pain, using knee osteoarthritis as a case study. The research aims to: 1) Use natural language processing to annotate patient narratives and...